Abstract | PURPOSE: The aim of this study was to determine the anti-inflammatory effects of besifloxacin, a novel fluoroquinolone under clinical evaluation for the treatment of ophthalmic infections, in human corneal epithelial cells (HCEpiC). METHODS: RESULTS: Stimulation of HCEpiC with IL-1beta increased release of 12 of the 29 cytokines measured. Besifloxacin significantly inhibited IL-1beta-induced cytokine release in a dose-dependent manner, with a comparable (IL-8) or better (G-CSF, GM-CSF, IL-6, MCP-1, MIP-1beta, TGF-alpha, and TNF-alpha) efficacy compared to moxifloxacin. A significant inhibitory effect of besifloxacin was observed at 1 or 10 microg/ml. Besifloxacin inhibited IkappaB degradation, NFkappaB nuclear translocation, and activation of p38 and JNK MAPKs. Based on improvement of clinical score, besifloxacin showed statistically significant anti-inflammatory effect compared to saline treatment. CONCLUSIONS:
Besifloxacin acts as an anti-inflammatory agent in corneal epithelial cells in vitro, by inhibiting the NFkappaB and MAPK pathways. Besifloxacin also exhibits anti-inflammatory efficacy in vivo. The anti-inflammatory attribute may enhance its efficacy in the treatment of ocular infections with an inflammatory component and warrants further investigation.
|
Authors | Jin-Zhong Zhang, Megan E Cavet, Keith W Ward |
Journal | Current eye research
(Curr Eye Res)
Vol. 33
Issue 11
Pg. 923-32
(Nov 2008)
ISSN: 1460-2202 [Electronic] England |
PMID | 19085374
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents
- Aza Compounds
- Azepines
- Cytokines
- Fluoroquinolones
- Interleukin-1beta
- NF-kappa B
- Quinolines
- besifloxacin
- Mitogen-Activated Protein Kinases
- Moxifloxacin
|
Topics |
- Animals
- Anti-Inflammatory Agents
(administration & dosage, pharmacology)
- Aza Compounds
(pharmacology)
- Azepines
(administration & dosage, pharmacology)
- Biological Transport
(drug effects)
- Cell Nucleus
(metabolism)
- Cells, Cultured
- Cytokines
(antagonists & inhibitors, metabolism)
- Dose-Response Relationship, Drug
- Endophthalmitis
(pathology)
- Enzyme Activation
(drug effects)
- Epithelium, Corneal
(cytology, drug effects)
- Female
- Fluoroquinolones
(administration & dosage, pharmacology)
- Humans
- Interleukin-1beta
(pharmacology)
- Mitogen-Activated Protein Kinases
(metabolism)
- Moxifloxacin
- NF-kappa B
(metabolism)
- Quinolines
(pharmacology)
- Rabbits
|